Solid Biosciences Inc. Investment Income, Interest
Solid Biosciences Inc. (SLDB) reported Investment Income, Interest of $3.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-06
- Solid Biosciences Inc. investment income, interest for the quarter ending 2026-06-30 was $3.22M, a 8.60% increase year-over-year.
- Solid Biosciences Inc. investment income, interest for the quarter ending 2026-03-31 was $2.06M, a 10.26% decline year-over-year.
- Solid Biosciences Inc. investment income, interest for the quarter ending 2025-12-31 was $2.05M, a 6.60% increase year-over-year.
- Solid Biosciences Inc. investment income, interest for the quarter ending 2025-09-30 was $2.59M, a 11.08% increase year-over-year.
- Solid Biosciences Inc. investment income, interest for fiscal 2025 was $9.90M, a 4.59% increase from fiscal 2024.
- Solid Biosciences Inc. investment income, interest for fiscal 2024 was $9.47M, a 24.89% increase from fiscal 2023.
- Solid Biosciences Inc. investment income, interest for fiscal 2023 was $7.58M, a 189.83% increase from fiscal 2022.
- Solid Biosciences Inc. investment income, interest for fiscal 2022 was $2.62M, a 3987.50% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 3 month as first filed | Investment Income, Interest 6 month | Investment Income, Interest 6 month as first filed | Investment Income, Interest 9 month | Investment Income, Interest 9 month as first filed | Investment Income, Interest 12 month | Investment Income, Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.22M 10-Q · filed 2026-08-06 | $5.29M 10-Q · filed 2026-08-06 | $7.34M derived: sum of 3 quarters · filed 2026-08-06 | $9.92M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $2.06M 10-Q · filed 2026-05-12 | $4.12M derived: sum of 2 quarters · filed 2026-05-12 | $6.70M derived: sum of 3 quarters · filed 2026-05-12 | $9.67M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $4.64M derived: sum of 2 quarters · filed 2026-03-19 | $7.60M derived: sum of 3 quarters · filed 2026-08-06 | $9.90M 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $2.59M 10-Q · filed 2025-11-03 | $5.55M derived: sum of 2 quarters · filed 2026-08-06 | $7.85M 10-Q · filed 2025-11-03 | $9.78M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $2.97M 10-Q · filed 2026-08-06 | $5.27M 10-Q · filed 2026-08-06 | $7.19M derived: sum of 3 quarters · filed 2026-08-06 | $9.52M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $2.30M 10-Q · filed 2026-05-12 | $4.22M derived: sum of 2 quarters · filed 2026-05-12 | $6.55M derived: sum of 3 quarters · filed 2026-05-12 | $9.12M derived: sum of 4 quarters · filed 2026-05-12 | ||||
| 2024-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $4.25M derived: sum of 2 quarters · filed 2026-03-19 | $6.82M derived: sum of 3 quarters · filed 2026-03-19 | $9.47M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | $2.33M 10-Q · filed 2025-11-03 | $4.89M derived: sum of 2 quarters · filed 2025-11-03 | $7.54M 10-Q · filed 2025-11-03 | $9.30M derived: sum of 4 quarters · filed 2025-11-03 | ||||
| 2024-06-30 | $2.56M 10-Q · filed 2025-08-12 | $5.22M 10-Q · filed 2025-08-12 | $6.98M derived: sum of 3 quarters · filed 2025-08-12 | $8.94M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $2.65M 10-Q · filed 2025-05-15 | $4.41M derived: sum of 2 quarters · filed 2025-05-15 | $6.37M derived: sum of 3 quarters · filed 2025-05-15 | $8.43M derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $3.72M derived: sum of 2 quarters · filed 2025-03-06 | $5.78M derived: sum of 3 quarters · filed 2025-03-06 | $7.58M 10-K · filed 2025-03-06 | $7.14M 10-K · filed 2024-03-13 | |||
| 2023-09-30 | $1.96M 10-Q · filed 2024-11-06 | $1.86M 10-Q · filed 2023-11-08 | $4.02M derived: sum of 2 quarters · filed 2024-11-06 | $5.82M 10-Q · filed 2024-11-06 | $5.48M 10-Q · filed 2023-11-08 | $7.36M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $2.06M 10-Q · filed 2024-08-13 | $1.95M 10-Q · filed 2023-08-14 | $3.86M 10-Q · filed 2024-08-13 | $3.63M 10-Q · filed 2023-08-14 | $5.39M derived: sum of 3 quarters · filed 2024-08-13 | $6.13M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $1.80M 10-Q · filed 2024-05-15 | $1.68M 10-Q · filed 2023-05-11 | $3.33M derived: sum of 2 quarters · filed 2024-05-15 | $4.07M derived: sum of 3 quarters · filed 2024-05-15 | $4.36M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $2.27M derived: sum of 2 quarters · filed 2024-03-13 | $2.56M derived: sum of 3 quarters · filed 2024-03-13 | $2.62M 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | $735.00K 10-Q · filed 2023-11-08 | $1.03M derived: sum of 2 quarters · filed 2023-11-08 | $1.08M 10-Q · filed 2023-11-08 | |||||
| 2022-06-30 | $293.00K 10-Q · filed 2023-08-14 | $347.00K 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | $54.00K 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | $64.00K 10-K · filed 2024-03-13 | |||||||
| 2020-12-31 | $115.00K 10-K · filed 2023-03-23 | |||||||
| 2020-03-31 | $164.00K 10-Q · filed 2020-05-07 | $463.00K derived: sum of 2 quarters · filed 2022-03-14 | $869.00K derived: sum of 3 quarters · filed 2022-03-14 | $1.24M derived: sum of 4 quarters · filed 2022-03-14 | ||||
| 2019-12-31 | $299.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $705.00K derived: sum of 2 quarters · filed 2022-03-14 | $1.07M derived: sum of 3 quarters · filed 2022-03-14 | $1.58M 10-K · filed 2022-03-14 | ||||
| 2019-09-30 | $406.00K 10-Q · filed 2019-11-12 | $773.00K derived: sum of 2 quarters · filed 2019-11-12 | $1.28M 10-Q · filed 2019-11-12 | $1.66M derived: sum of 4 quarters · filed 2021-03-15 | ||||
| 2019-06-30 | $367.00K 10-Q · filed 2019-08-14 | $875.00K 10-Q · filed 2019-08-14 | $1.26M derived: sum of 3 quarters · filed 2021-03-15 | $1.35M derived: sum of 4 quarters · filed 2021-03-15 | ||||
| 2019-03-31 | $508.00K 10-Q · filed 2020-05-07 | $890.00K derived: sum of 2 quarters · filed 2021-03-15 | $982.00K derived: sum of 3 quarters · filed 2021-03-15 | $1.06M derived: sum of 4 quarters · filed 2021-03-15 | ||||
| 2018-12-31 | $382.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $474.00K derived: sum of 2 quarters · filed 2021-03-15 | $554.00K derived: sum of 3 quarters · filed 2021-03-15 | $619.00K 10-K · filed 2021-03-15 | ||||
| 2018-09-30 | $92.00K 10-Q · filed 2019-11-12 | $172.00K derived: sum of 2 quarters · filed 2019-11-12 | $237.00K 10-Q · filed 2019-11-12 | $291.00K derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-06-30 | $80.00K 10-Q · filed 2019-08-14 | $145.00K 10-Q · filed 2019-08-14 | $199.00K derived: sum of 3 quarters · filed 2020-03-12 | $250.00K derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2018-03-31 | $65.00K 10-Q · filed 2019-05-13 | $119.00K derived: sum of 2 quarters · filed 2020-03-12 | $170.00K derived: sum of 3 quarters · filed 2020-03-12 | $222.00K derived: sum of 4 quarters · filed 2020-03-12 | ||||
| 2017-12-31 | $54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $105.00K derived: sum of 2 quarters · filed 2020-03-12 | $157.00K derived: sum of 3 quarters · filed 2020-03-12 | $219.00K 10-K · filed 2020-03-12 | ||||
| 2017-09-30 | $51.00K 10-Q · filed 2018-11-13 | $103.00K derived: sum of 2 quarters · filed 2018-11-13 | $165.00K 10-Q · filed 2018-11-13 | |||||
| 2017-06-30 | $52.00K 10-Q · filed 2018-08-10 | $114.00K 10-Q · filed 2018-08-10 | ||||||
| 2017-03-31 | $62.00K 10-Q · filed 2018-05-10 | |||||||
| 2016-12-31 | $369.00K 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |